Current SATVI news
SATVI researchers Miguel Rodo, Professor Tom Scriba, Drs. Virginie Rozot, Elisa Nemes and Profesor Mark Hatherill have published a article titled: "A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates" appearing in the PLoS Pathogens journal.
The South African Tuberculosis Vaccine Initiative 2018 Annual Report is now available.
SATVI Authors Professors Mark Hatherill, Tom Scriba, Dr Munyaradzi Musvosvi, Humphrey Mulenga, Ashley Veldsman have co-authored a research paper titled "Toll-like receptor chaperone HSP90B1 and the immune response to Mycobacteria" appearing in the PLos One Journal.
Professor Tom Scriba and Dr Adam Penn-Nicholson have co-authored a research publication titled: "Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases" appearing in the Mucosal Immunology Journal.
Professor Mark Hatherill has co-authored a journal article titled "Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting" appearing in the Tuberculosis (Edinb) Journal.
Professor Tom Scriba has co-authored a paper titled: “Metabolite changes in blood predict the onset of tuberculosis” in the Nature Journal.
Prof Mark Hatherill has co-authored a journal article titled: "Safety and Immunogenicity of early Bacillus Calmette-Guerin (BCG) vaccination in infants who are preterm and/or have low birth weights: A systematic review and meta-analysis" appearing in the Journal of American Medical Association (JAMA).
SATVI Director Professor Mark Hatherill has co-authored a commentary titled "WHO preferred product characteristics for new vaccines against tuberculosis" appearing in The Lancet journal.
Associate Professor Tom Scriba has co authored a paper titled "Can we predict tuberculosis cure? What tools are available?" appearing in the European Respiratory Journal of the European Respiratory Society.
Watch the press conference during which the primary results from the M72/AS01E candidate vaccine were announced during the Union World Conference on Lung Health. Professor Mark Hatherill, SATVI Director spoke on behalf of SATVI.
View the full list of SATVI speakers at the The Union World Conference on Lung Health held from 24 to 27 October 2018.
The New England Journal of Medicine has just published the primary results of an ongoing phase IIb clinical trial testing the candidate tuberculosis vaccine M72/AS01E which demonstrates that the M72/AS01E vaccine significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults who were already infected with latent TB at the time of vaccination.